Publication Results

Generate Report

Add publications by marking their checkboxes, or

Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program Study.

Asare M,  Heckler CE,  Culakova E,  Kamen CS,  Kleckner AS,  Minasian LM,  Wendler DS,  Feige M,  Weil CJ,  Long J,  Cole SK,  Onitilo AA,  Peppone LJ,  Morrow GR,  Janelsins MC
J Cancer Educ 2020 Apr;35(2):292-300
Major Program(s) or Research Group(s): NCI Community Oncology Research Program ;  Office of the Director
PubMed ID: 30612315
PMC ID: PMC6612536

Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

Xu Z,  Becerra AZ,  Justiniano CF,  Aquina CT,  Fleming FJ,  Boscoe FP,  Schymura MJ,  Sinno AK,  Chaoul J,  Morrow GR,  Minasian L,  Temkin SM
J Surg Res 2020 Feb;246:34-41
Major Program(s) or Research Group(s): NCI Community Oncology Research Program ;  Office of the Director
PubMed ID: 31561176
PMC ID: PMC6917987 [available on February 01, 2021]

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).

Crew KD,  Anderson GL,  Hershman DL,  Terry MB,  Tehranifar P,  Lew DL,  Yee M,  Brown EA,  Kairouz SS,  Kuwajerwala N,  Bevers T,  Doster JE,  Zarwan C,  Kruper L,  Minasian LM,  Ford L,  Arun B,  Neuhouser M,  Goodman GE,  Brown PH
Cancer Prev Res (Phila) 2019 Jul;12(7):481-490
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 31138522
PMC ID: PMC6609474

A Rare Opportunity: Examining the Experience of a New Institutional Review Board.

Parreco L,  Rooney L,  Hampp S,  Brown A,  Minasian L
J Empir Res Hum Res Ethics 2019 Jul;14(3):274-285
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 31104551
PMC ID: PMC6565466

Improving attribution of adverse events in oncology clinical trials.

George GC,  Barata PC,  Campbell A,  Chen A,  Cortes JE,  Hyman DM,  Jones L,  Karagiannis T,  Klaar S,  Le-Rademacher JG,  LoRusso P,  Mandrekar SJ,  Merino DM,  Minasian LM,  Mitchell SA,  Montez S,  O'Connor DJ,  Pettit S,  Silk E,  Sloan JA,  Stewart M,  Takimoto CH,  Wong GY,  Yap TA,  Cleeland CS,  Hong DS
Cancer Treat Rev 2019 Jun;76:33-40
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 31108240
PMC ID: not available

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Chung AE,  Shoenbill K,  Mitchell SA,  Dueck AC,  Schrag D,  Bruner DW,  Minasian LM,  St Germain D,  O'Mara AM,  Baumgartner P,  Rogak LJ,  Abernethy AP,  Griffin AC,  Basch EM
J Am Med Inform Assoc 2019 Apr 1;26(4):276-285
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 30840079
PMC ID: PMC6402312

Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer.

Samimi G,  Heckman-Stoddard BM,  Kay SS,  Bloodgood B,  Coa KI,  Robinson JL,  Tennant B,  Ford LG,  Szabo E,  Minasian L
Cancer Prev Res (Phila) 2019 Apr;12(4):271-282
Major Program(s) or Research Group(s): Breast and Gynecologic CancerLung and Upper Aerodigestive Cancer ;  Office of the Director
PubMed ID: 30824471
PMC ID: PMC6445710

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Shepshelovich D,  McDonald K,  Spreafico A,  Razak ARA,  Bedard PL,  Siu LL,  Minasian L,  Hansen AR
Oncologist 2019 Apr;24(4):e146-e148
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 30728278
PMC ID: PMC6459233

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation.

Unger JM,  Vaidya R,  Hershman DL,  Minasian LM,  Fleury ME
J Natl Cancer Inst 2019 Mar 1;111(3):245-255
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 30856272
PMC ID: PMC6410951

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF,  Unger JM,  Phillips KA,  Boyle F,  Hitre E,  Moseley A,  Porter DJ,  Francis PA,  Goldstein LJ,  Gomez HL,  Vallejos CS,  Partridge AH,  Dakhil SR,  Garcia AA,  Gralow JR,  Lombard JM,  Forbes JF,  Martino S,  Barlow WE,  Fabian CJ,  Minasian LM,  Meyskens FL,  Gelber RD,  Hortobagyi GN,  Albain KS
J Natl Cancer Inst 2019 Feb 1;111(2):210-213
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 30371800
PMC ID: PMC6657277

Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants.

Moss JL,  Murphy J,  Filiaci VL,  Wenzel LB,  Minasian L,  Temkin SM
Support Care Cancer 2019 Feb;27(2):531-538
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 30003341
PMC ID: PMC6330149

Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®.

Silver MI,  Klein W,  Samimi G,  Minasian L,  Loud J,  Roberts MC
Breast Cancer Res Treat 2019 Feb;173(3):719-726
Major Program(s) or Research Group(s): Breast and Gynecologic CancerCancer Prevention Fellowship Program ;  Office of the Director
PubMed ID: 30413980
PMC ID: not available

Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Shelburne N,  Simonds NI,  Adhikari B,  Alley M,  Desvigne-Nickens P,  Dimond E,  Filipski K,  Gallicchio L,  Minasian L
Curr Oncol Rep 2019 Jan 30;21(1):9
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 30701318
PMC ID: not available

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

Goodman PJ,  Tangen CM,  Darke AK,  Lucia MS,  Ford LG,  Minasian LM,  Parnes HL,  LeBlanc ML,  Thompson IM Jr
N Engl J Med 2019 Jan 24;380(4):393-394
Major Program(s) or Research Group(s): NCI Community Oncology Research Program ;  Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 30673548
PMC ID: not available

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

Shen S,  Unger JM,  Crew KD,  Till C,  Greenlee H,  Gralow J,  Dakhil SR,  Minasian LM,  Wade JL 3rd,  Fisch MJ,  Henry NL,  Hershman DL
Breast Cancer Res Treat 2018 Dec;172(3):603-610
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 30159789
PMC ID: PMC6681817

Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States

Freedman Andrew N.,  Klabunde Carrie N.,  Wiant Kristine,  Enewold Lindsey,  Gray Stacy W.,  Filipski Kelly K.,  Keating Nancy L.,  Leonard Debra G. B.,  Lively Tracy,  McNeel Timothy S.,  Minasian Lori,  Lpotosky Arnold,  Rivera Donna R.,  Schilsky Richard L.,  Schrag Deborah,  Simonds Naoko I,  Sineshaw Helmneh M.,  Struewing Jeffery P.,  Willis Gordon,  de Moor Janet S.
JCO Precis. Oncol. 2018 Nov 14;2
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: not available
PMC ID: not available

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G,  Minasian LM,  Baron F,  Cavalli F,  De Claro RA,  Dueck AC,  El-Galaly TC,  Everest N,  Geissler J,  Gisselbrecht C,  Gribben J,  Horowitz M,  Ivy SP,  Jacobson CA,  Keating A,  Kluetz PG,  Krauss A,  Kwong YL,  Little RF,  Mahon FX,  Matasar MJ,  Mateos MV,  McCullough K,  Miller RS,  Mohty M,  Moreau P,  Morton LM,  Nagai S,  Rule S,  Sloan J,  Sonneveld P,  Thompson CA,  Tzogani K,  van Leeuwen FE,  Velikova G,  Villa D,  Wingard JR,  Wintrich S,  Seymour JF,  Habermann TM
Lancet Haematol 2018 Nov;5(11):e563-e598
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29907552
PMC ID: PMC6261436

Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.

Janelsins MC,  Heckler CE,  Peppone LJ,  Ahles TA,  Mohile SG,  Mustian KM,  Palesh O,  O'Mara AM,  Minasian LM,  Williams AM,  Magnuson A,  Geer J,  Dakhil SR,  Hopkins JO,  Morrow GR
J Clin Oncol 2018 Sep 21 :JCO2018786624
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 30240328
PMC ID: PMC6225503

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

Basch E,  Dueck AC,  Rogak LJ,  Mitchell SA,  Minasian LM,  Denicoff AM,  Wind JK,  Shaw MC,  Heon N,  Shi Q,  Ginos B,  Nelson GD,  Meyers JP,  Chang GJ,  Mamon HJ,  Weiser MR,  Kolevska T,  Reeve BB,  Bruner DW,  Schrag D
J Clin Oncol 2018 Sep 11 :JCO2018788620
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 30204536
PMC ID: PMC6209091

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM,  Barlow WE,  Tangen CM,  Ramsey SD,  Thompson IM Jr,  Klein EA,  LeBlanc M,  Blanke CD,  Goodman PJ,  Minasian LM,  Nghiem VT,  Hershman DL
Cancer Epidemiol 2018 Aug;55:117-122
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 29936140
PMC ID: PMC6625804

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL,  Unger JM,  Greenlee H,  Capodice JL,  Lew DL,  Darke AK,  Kengla AT,  Melnik MK,  Jorgensen CW,  Kreisle WH,  Minasian LM,  Fisch MJ,  Henry NL,  Crew KD
JAMA 2018 Jul 10;320(2):167-176
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 29998338
PMC ID: PMC6583520

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).

Hershman DL,  Unger JM,  Crew KD,  Till C,  Greenlee H,  Minasian LM,  Moinpour CM,  Lew DL,  Fehrenbacher L,  Wade JL 3rd,  Wong SF,  Fisch MJ,  Lynn Henry N,  Albain KS
J Natl Cancer Inst 2018 Jun 1;110(6):669-676
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 29361042
PMC ID: PMC6005110

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

Kluetz PG,  Kanapuru B,  Lemery S,  Johnson LL,  Fiero MH,  Arscott K,  Barbachano Y,  Basch E,  Campbell M,  Cappelleri JC,  Cella D,  Cleeland C,  Coens C,  Daniels S,  Denlinger CS,  Fairclough DL,  Hillard JR,  Minasian L,  Mitchell SA,  O'Connor D,  Patel S,  Rubin EH,  Ryden A,  Soltys K,  Sridhara R,  Thanarajasingam G,  Velikova G,  Coons SJ
Value Health 2018 Jun;21(6):742-747
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29909880
PMC ID: not available

Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.

Pinsky PF,  Miller E,  Heckman-Stoddard B,  Minasian L
Am J Obstet Gynecol 2018 Jun;218(6):606.e1-606.e9
Major Program(s) or Research Group(s): Breast and Gynecologic CancerEarly Detection ;  Office of the Director
PubMed ID: 29630889
PMC ID: PMC5970073

Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials.

Minasian LM,  Frazier AL,  Sung L,  O'Mara A,  Kelaghan J,  Chang KW,  Krailo M,  Pollock BH,  Reaman G,  Freyer DR
Cancer Med 2018 May 30
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 29846043
PMC ID: PMC6051159

Incorporating Patient-Reported Outcomes Into Early-Phase Trials

Chen Alice P,  Mitchell Sandra A,  Minasian Lori M,  St Germain Diane C
2018 May 26
Kummar Shivaani,  Takimoto Chris
Novel Designs of Early Phase Trials for Cancer Therapeutics
ISBN: 978-0-12-812570-0; 978-0-12-812512-0
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director

Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States.

Temkin SM,  Kohn EC,  Penberthy L,  Cronin KA,  Rubinsak L,  Dickie LA,  Minasian L,  Noone AM
Cancer Causes Control 2018 May;29(4-5):427-433
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29497884
PMC ID: not available

Meeting the Challenge: The National Cancer Institute's Central Institutional Review Board for Multi-Site Research.

Massett HA,  Hampp SL,  Goldberg JL,  Mooney M,  Parreco LK,  Minasian L,  Montello M,  Mishkin GE,  Davis C,  Abrams JS
J Clin Oncol 2018 Mar 10;36(8):819-824
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29384720
PMC ID: PMC5844669

What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.

Atkinson TM,  Hay JL,  Dueck AC,  Mitchell SA,  Mendoza TR,  Rogak LJ,  Minasian LM,  Basch E
J Pain Symptom Manage 2018 Mar;55(3):e3-e6
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29129739
PMC ID: PMC6317851

Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Samimi G,  Trabert B,  Duggan MA,  Robinson JL,  Coa KI,  Waibel E,  Garcia E,  Minasian LM,  Sherman ME
Gynecol Oncol 2018 Mar;148(3):515-520
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 29395311
PMC ID: PMC5829019

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM,  Nair J,  Zimmer A,  Lipkowitz S,  Annunziata CM,  Merino MJ,  Swisher EM,  Harrell MI,  Trepel JB,  Lee MJ,  Bagheri MH,  Botesteanu DA,  Steinberg SM,  Minasian L,  Ekwede I,  Kohn EC
Lancet Oncol 2018 Feb;19(2):207-215
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29361470
PMC ID: PMC7366122

Ovarian Cancer Prevention in High-risk Women.

Temkin SM,  Bergstrom J,  Samimi G,  Minasian L
Clin Obstet Gynecol 2017 Dec;60(4):738-757
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 28957949
PMC ID: PMC5920567

Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.

Temkin SM,  Miller EA,  Samimi G,  Berg CD,  Pinsky P,  Minasian L
Eur J Cancer 2017 Dec;87:182-188
Major Program(s) or Research Group(s): Breast and Gynecologic CancerEarly Detection ;  Office of the Director ;  Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
PubMed ID: 29156299
PMC ID: not available

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM,  Hays JL,  Chiou VL,  Annunziata CM,  Swisher EM,  Harrell MI,  Yu M,  Gordon N,  Sissung TM,  Ji J,  Figg WD,  Minasian L,  Lipkowitz S,  Wood BJ,  Doroshow J,  Kohn EC
Oncotarget 2017 Oct 3;8(45):79175-79187
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 29108297
PMC ID: PMC5668030

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

Lee SM,  Zhang Y,  Minasian LM,  Unger JM,  Hershman DL
Cancer Invest 2017 Aug 9;35(7):484-489
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 28692317
PMC ID: not available

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E,  Dueck AC,  Rogak LJ,  Minasian LM,  Kelly WK,  O'Mara AM,  Denicoff AM,  Seisler D,  Atherton PJ,  Paskett E,  Carey L,  Dickler M,  Heist RS,  Himelstein A,  Rugo HS,  Sikov WM,  Socinski MA,  Venook AP,  Weckstein DJ,  Lake DE,  Biggs DD,  Freedman RA,  Kuzma C,  Kirshner JJ,  Schrag D
JAMA Oncol 2017 Aug 1;3(8):1043-1050
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Supportive Care and Symptom ManagementNCI Community Oncology Research Program
PubMed ID: 28208174
PMC ID: PMC5553624

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Skates SJ,  Greene MH,  Buys SS,  Mai PL,  Brown P,  Piedmonte M,  Rodriguez G,  Schorge JO,  Sherman M,  Daly MB,  Rutherford T,  Brewster WR,  O'Malley DM,  Partridge E,  Boggess J,  Drescher CW,  Isaacs C,  Berchuck A,  Domchek S,  Davidson SA,  Edwards R,  Elg SA,  Wakeley K,  Phillips KA,  Armstrong D,  Horowitz I,  Fabian CJ,  Walker J,  Sluss PM,  Welch W,  Minasian L,  Horick NK,  Kasten CH,  Nayfield S,  Alberts D,  Finkelstein DM,  Lu KH
Clin Cancer Res 2017 Jul 15;23(14):3628-3637
Major Program(s) or Research Group(s): Breast and Gynecologic CancerEarly Detection ;  Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 28143870
PMC ID: PMC5726402

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Samimi G,  Bernardini MQ,  Brody LC,  Caga-Anan CF,  Campbell IG,  Chenevix-Trench G,  Couch FJ,  Dean M,  de Hullu JA,  Domchek SM,  Drapkin R,  Spencer Feigelson H,  Friedlander M,  Gaudet MM,  Harmsen MG,  Hurley K,  James PA,  Kwon JS,  Lacbawan F,  Lheureux S,  Mai PL,  Mechanic LE,  Minasian LM,  Myers ER,  Robson ME,  Ramus SJ,  Rezende LF,  Shaw PA,  Slavin TP,  Swisher EM,  Takenaka M,  Bowtell DD,  Sherman ME
J Clin Oncol 2017 Jul 10;35(20):2329-2337
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 28398847
PMC ID: PMC5501360

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ,  Lee JM,  Roth J,  Rodgers L,  Nguyen J,  Annunziata CM,  Minasian L,  Kohn EC,  Figg WD
Cancer Chemother Pharmacol 2017 Jul;80(1):165-175
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 28577239
PMC ID: PMC6361113

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Basch E,  Pugh SL,  Dueck AC,  Mitchell SA,  Berk L,  Fogh S,  Rogak LJ,  Gatewood M,  Reeve BB,  Mendoza TR,  O'Mara AM,  Denicoff AM,  Minasian LM,  Bennett AV,  Setser A,  Schrag D,  Roof K,  Moore JK,  Gergel T,  Stephans K,  Rimner A,  DeNittis A,  Bruner DW
Int J Radiat Oncol Biol Phys 2017 Jun 1;98(2):409-418
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Supportive Care and Symptom ManagementNCI Community Oncology Research Program
PubMed ID: 28463161
PMC ID: PMC5557037

Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables.

Chandwani KD,  Zhao F,  Morrow GR,  Deshields TL,  Minasian LM,  Manola J,  Fisch MJ
J Pain Symptom Manage 2017 Jun;53(6):988-998
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 28185892
PMC ID: PMC5474148

Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?

Samimi G,  Minasian LM
Cancer 2017 May 15;123(10):1699-1702
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 28334415
PMC ID: not available

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM,  Peer CJ,  Yu M,  Amable L,  Gordon N,  Annunziata CM,  Houston N,  Goey AK,  Sissung TM,  Parker B,  Minasian L,  Chiou VL,  Murphy RF,  Widemann BC,  Figg WD,  Kohn EC
Clin Cancer Res 2017 Mar 15;23(6):1397-1406
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 27663600
PMC ID: PMC5354956

Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention.

Lance P,  Alberts DS,  Thompson PA,  Fales L,  Wang F,  San Jose J,  Jacobs ET,  Goodman PJ,  Darke AK,  Yee M,  Minasian L,  Thompson IM,  Roe DJ
Cancer Prev Res (Phila) 2017 Jan;10(1):45-54
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 27777235
PMC ID: PMC5510661

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.

Mishkin G,  Minasian LM,  Kohn EC,  Noone AM,  Temkin SM
Gynecol Oncol 2016 Dec;143(3):611-616
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 27697287
PMC ID: not available

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Unger JM,  Till C,  Thompson IM Jr,  Tangen CM,  Goodman PJ,  Wright JD,  Barlow WE,  Ramsey SD,  Minasian LM,  Hershman DL
J Natl Cancer Inst 2016 Dec;108(12)
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 27565902
PMC ID: PMC5241895

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

Hershman DL,  Till C,  Wright JD,  Awad D,  Ramsey SD,  Barlow WE,  Minasian LM,  Unger J
J Clin Oncol 2016 Sep 1;34(25):3014-22
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 27325863
PMC ID: PMC5012713

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Sherman ME,  Drapkin RI,  Horowitz NS,  Crum CP,  Friedman S,  Kwon JS,  Levine DA,  Shih IeM,  Shoupe D,  Swisher EM,  Walker J,  Trabert B,  Greene MH,  Samimi G,  Temkin SM,  Minasian LM
Cancer Prev Res (Phila) 2016 Sep;9(9):713-20
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director
PubMed ID: 27221539
PMC ID: PMC5010984

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.

Goodman PJ,  Tangen CM,  Darke AK,  Arnold KB,  Hartline J,  Yee M,  Anderson K,  Caban-Holt A,  Christen WG,  Cassano PA,  Lance P,  Klein EA,  Crowley JJ,  Minasian LM,  Meyskens FL
Trials 2016 Aug 12;17:400
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 27519183
PMC ID: PMC4983010

Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress.

Guertin KA,  Grant RK,  Arnold KB,  Burwell L,  Hartline J,  Goodman PJ,  Minasian LM,  Lippman SM,  Klein E,  Cassano PA
Free Radic Biol Med 2016 Jun;95:349-56
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 27012420
PMC ID: PMC4867301
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

Lee SM,  Backenroth D,  Cheung YK,  Hershman DL,  Vulih D,  Anderson B,  Ivy P,  Minasian L
J Clin Oncol 2016 Apr 20;34(12):1395-401
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 26926682
PMC ID: PMC5070578

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.

Jang S,  Zheng C,  Tsai HT,  Fu AZ,  Barac A,  Atkins MB,  Freedman AN,  Minasian L,  Potosky AL
Cancer 2016 Jan 1;122(1):124-30
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 26439451
PMC ID: PMC4602387

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.

Ligibel JA,  Alfano CM,  Hershman D,  Ballard RM,  Bruinooge SS,  Courneya KS,  Daniels EC,  Demark-Wahnefried W,  Frank ES,  Goodwin PJ,  Irwin ML,  Levit LA,  McCaskill-Stevens W,  Minasian LM,  O'Rourke MA,  Pierce JP,  Stein KD,  Thomson CA,  Hudis CA
J Clin Oncol 2015 Nov 20;33(33):3961-7
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 26324364
PMC ID: not available

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Dueck AC,  Mendoza TR,  Mitchell SA,  Reeve BB,  Castro KM,  Rogak LJ,  Atkinson TM,  Bennett AV,  Denicoff AM,  O'Mara AM,  Li Y,  Clauser SB,  Bryant DM,  Bearden JD 3rd,  Gillis TA,  Harness JK,  Siegel RD,  Paul DB,  Cleeland CS,  Schrag D,  Sloan JA,  Abernethy AP,  Bruner DW,  Minasian LM,  Basch E,  National Cancer Institute PRO-CTCAE Study Group
JAMA Oncol 2015 Nov;1(8):1051-9
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 26270597
PMC ID: PMC4857599

A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT)

Dueck Amylou C.,  Mitchell Sandra A.,  Rogak Lauren J.,  Ginos Brenda,  Sargent Daniel J.,  Shi Qian,  Farma Jeffrey M.,  Eng Cathy,  Crane Christopher,  Kennecke Hagen,  O'Mara Ann M.,  Minasian Lori M.,  Schrag Deborah,  Basch Ethan
Qual Life Res 2015 Oct 1;24(1 Suppl):1-2
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Supportive Care and Symptom Management
PubMed ID: not available
PMC ID: not available

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Minasian LM,  Tangen CM,  Wickerham DL
Semin Oncol 2015 Oct;42(5):748-63
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 26433556
PMC ID: PMC4593316

Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women's cancers

Chiou Victoria L.,  Annunziata Christina,  Lipkowitz Stanley,  Minasian Lori,  Gordon Nicolas,  Yu Minshu,  Steinberg Seth,  Houston Nicole,  Kohn Elise,  Lee Jung-min
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract CT326
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: not available
PMC ID: not available

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Hershman DL,  Unger JM,  Crew KD,  Awad D,  Dakhil SR,  Gralow J,  Greenlee H,  Lew DL,  Minasian LM,  Till C,  Wade JL 3rd,  Meyskens FL,  Moinpour CM
J Clin Oncol 2015 Jun 10;33(17):1910-7
Major Program(s) or Research Group(s): Lung and Upper Aerodigestive Cancer ;  Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 25940724
PMC ID: PMC4451174

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418).

Chiou Victoria L.,  Kohn Elise C.,  Annunziata Christina M.,  Minasian Lori M.,  Lipkowitz Stan,  Yu Minshu,  Gordon Nicolas,  Houston Nicole D.,  Lee Jung-min
J Clin Oncol 2015 May 20;33(15):Abstract 5514
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: not available
PMC ID: not available

Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma.

Jang Sekwon,  Zheng Chaoyi,  Tsai Huei-Ting,  Fu Alex Z.,  Barac Ana,  Atkins Michael B.,  Freeman Andrew N.,  Minasian Lori M.,  Potosky Arnold L.
J Clin Oncol 2015 May 20;33(15):Abstract 4544
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: not available
PMC ID: not available

SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac): A randomized, double-blind, placebo-controlled phase III clinical trial.

Zell Jason A.,  Unger Joseph M.,  Anderson Garnet L.,  Cook Elise D.,  Krouse Robert S.,  Lance M. Peter,  Minasian Lori M.,  Ford Leslie,  Brown Powel
J Clin Oncol 2015 May 20;33(15):Abstract TPS3627
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: not available
PMC ID: not available

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Lubet RA,  Scheiman JM,  Bode A,  White J,  Minasian L,  Juliana MM,  Boring DL,  Steele VE,  Grubbs CJ
Cancer Prev Res (Phila) 2015 Apr;8(4):296-302
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 25762530
PMC ID: PMC4383706

A randomized controlled trial of vitamin E and selenium on rate of decline in lung function.

Cassano PA,  Guertin KA,  Kristal AR,  Ritchie KE,  Bertoia ML,  Arnold KB,  Crowley JJ,  Hartline J,  Goodman PJ,  Tangen CM,  Minasian LM,  Lippman SM,  Klein E
Respir Res 2015 Mar 11;16:35
Major Program(s) or Research Group(s): Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 25889509
PMC ID: PMC4404242

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC,  Unger JM,  Phillips KA,  Boyle F,  Hitre E,  Porter D,  Francis PA,  Goldstein LJ,  Gomez HL,  Vallejos CS,  Partridge AH,  Dakhil SR,  Garcia AA,  Gralow J,  Lombard JM,  Forbes JF,  Martino S,  Barlow WE,  Fabian CJ,  Minasian L,  Meyskens FL Jr,  Gelber RD,  Hortobagyi GN,  Albain KS,  POEMS/S0230 Investigators
N Engl J Med 2015 Mar 5;372(10):923-32
Major Program(s) or Research Group(s): Office of the Director ;  Supportive Care and Symptom ManagementNCI Community Oncology Research Program
PubMed ID: 25738668
PMC ID: PMC4405231

Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial.

Christen WG,  Glynn RJ,  Gaziano JM,  Darke AK,  Crowley JJ,  Goodman PJ,  Lippman SM,  Lad TE,  Bearden JD,  Goodman GE,  Minasian LM,  Thompson IM Jr,  Blanke CD,  Klein EA
JAMA Ophthalmol 2015 Jan;133(1):17-24
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic CancerNCI Community Oncology Research Program
PubMed ID: 25232809
PMC ID: PMC4395006
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000).

Arnold KB,  Hermos JA,  Anderson KB,  Minasian L,  Tangen CM,  Probstfield JF,  Cook ED
Cancer Epidemiol Biomarkers Prev 2014 Dec;23(12):2895-905
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic CancerNCI Community Oncology Research Program
PubMed ID: 25242051
PMC ID: PMC4257858
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Optimizing dosing of oncology drugs.

Minasian L,  Rosen O,  Auclair D,  Rahman A,  Pazdur R,  Schilsky RL
Clin Pharmacol Ther 2014 Nov;96(5):572-9
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 25105705
PMC ID: not available

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Sherman ME,  Piedmonte M,  Mai PL,  Ioffe OB,  Ronnett BM,  Van Le L,  Ivanov I,  Bell MC,  Blank SV,  DiSilvestro P,  Hamilton CA,  Tewari KS,  Wakeley K,  Kauff ND,  Yamada SD,  Rodriguez G,  Skates SJ,  Alberts DS,  Walker JL,  Minasian L,  Lu K,  Greene MH
J Clin Oncol 2014 Oct 10;32(29):3275-83
Major Program(s) or Research Group(s): Breast and Gynecologic Cancer ;  Office of the Director ;  NCI Community Oncology Research Program
PubMed ID: 25199754
PMC ID: PMC4178524

Prevention and early detection of prostate cancer.

Cuzick J,  Thorat MA,  Andriole G,  Brawley OW,  Brown PH,  Culig Z,  Eeles RA,  Ford LG,  Hamdy FC,  Holmberg L,  Ilic D,  Key TJ,  La Vecchia C,  Lilja H,  Marberger M,  Meyskens FL,  Minasian LM,  Parker C,  Parnes HL,  Perner S,  Rittenhouse H,  Schalken J,  Schmid HP,  Schmitz-Dräger BJ,  Schröder FH,  Stenzl A,  Tombal B,  Wilt TJ,  Wolk A
Lancet Oncol 2014 Oct;15(11):e484-92
Major Program(s) or Research Group(s): Early DetectionLung and Upper Aerodigestive Cancer ;  Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 25281467
PMC ID: PMC4203149

Organizational and physician factors associated with patient enrollment in cancer clinical trials.

Jacobs SR,  Weiner BJ,  Reeve BB,  Weinberger M,  Minasian LM,  Good MJ
Clin Trials 2014 Oct;11(5):565-75
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 24902923
PMC ID: PMC4156916

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E,  Reeve BB,  Mitchell SA,  Clauser SB,  Minasian LM,  Dueck AC,  Mendoza TR,  Hay J,  Atkinson TM,  Abernethy AP,  Bruner DW,  Cleeland CS,  Sloan JA,  Chilukuri R,  Baumgartner P,  Denicoff A,  St Germain D,  O'Mara AM,  Chen A,  Kelaghan J,  Bennett AV,  Sit L,  Rogak L,  Barz A,  Paul DB,  Schrag D
J Natl Cancer Inst 2014 Sep;106(9)
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 25265940
PMC ID: PMC4200059

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

Shelburne N,  Adhikari B,  Brell J,  Davis M,  Desvigne-Nickens P,  Freedman A,  Minasian L,  Force T,  Remick SC
J Natl Cancer Inst 2014 Sep;106(9)
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsSupportive Care and Symptom Management
PubMed ID: 25210198
PMC ID: PMC4176042

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Gritz ER,  Arnold KB,  Moinpour CM,  Burton-Chase AM,  Tangen CM,  Probstfield JF,  See WA,  Lieber MM,  Caggiano V,  Moody-Thomas S,  Szczepanek C,  Ryan A,  Carlin S,  Hill S,  Goodman PJ,  Padberg RM,  Minasian LM,  Meyskens FL,  Thompson IM Jr
Cancer Epidemiol Biomarkers Prev 2014 Aug;23(8):1638-48
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Community Clinical Oncology Program ;  Prostate and Urologic CancerNCI Community Oncology Research Program
PubMed ID: 25028457
PMC ID: PMC4119542
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial.

Kristal AR,  Till C,  Song X,  Tangen CM,  Goodman PJ,  Neuhauser ML,  Schenk JM,  Thompson IM,  Meyskens FL Jr,  Goodman GE,  Minasian LM,  Parnes HL,  Klein EA
Cancer Epidemiol Biomarkers Prev 2014 Aug;23(8):1494-504
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  NCI Community Oncology Research Program
PubMed ID: 24732629
PMC ID: PMC4119495
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Reeve BB,  Mitchell SA,  Dueck AC,  Basch E,  Cella D,  Reilly CM,  Minasian LM,  Denicoff AM,  O'Mara AM,  Fisch MJ,  Chauhan C,  Aaronson NK,  Coens C,  Bruner DW
J Natl Cancer Inst 2014 Jul;106(7)
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 25006191
PMC ID: PMC4110472

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lee JM,  Hays JL,  Annunziata CM,  Noonan AM,  Minasian L,  Zujewski JA,  Yu M,  Gordon N,  Ji J,  Sissung TM,  Figg WD,  Azad N,  Wood BJ,  Doroshow J,  Kohn EC
J Natl Cancer Inst 2014 Jun;106(6):dju089
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 24842883
PMC ID: PMC4049120

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Kristal AR,  Darke AK,  Morris JS,  Tangen CM,  Goodman PJ,  Thompson IM,  Meyskens FL Jr,  Goodman GE,  Minasian LM,  Parnes HL,  Lippman SM,  Klein EA
J Natl Cancer Inst 2014 Mar;106(3):djt456
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  NCI Community Oncology Research Program
PubMed ID: 24563519
PMC ID: PMC3975165
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Hay JL,  Atkinson TM,  Reeve BB,  Mitchell SA,  Mendoza TR,  Willis G,  Minasian LM,  Clauser SB,  Denicoff A,  O'Mara A,  Chen A,  Bennett AV,  Paul DB,  Gagne J,  Rogak L,  Sit L,  Viswanath V,  Schrag D,  Basch E,  NCI PRO-CTCAE Study Group
Qual Life Res 2014 Feb;23(1):257-69
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 23868457
PMC ID: PMC3896507

Phase III prostate cancer chemoprevention trials.

Parnes HL,  Brawley OW,  Minasian LM,  Ford LG
Recent Results Cancer Res 2014;202:73-7
Major Program(s) or Research Group(s): Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 24531780
PMC ID: not available

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

Moon DH,  Lee JM,  Noonan AM,  Annunziata CM,  Minasian L,  Houston N,  Hays JL,  Kohn EC
Br J Cancer 2013 Aug 20;109(4):1072-8
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 23867999
PMC ID: PMC3749564

Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr,  Goodman PJ,  Tangen CM,  Parnes HL,  Minasian LM,  Godley PA,  Lucia MS,  Ford LG
N Engl J Med 2013 Aug 15;369(7):603-10
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 23944298
PMC ID: PMC4141537
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Brasky TM,  Darke AK,  Song X,  Tangen CM,  Goodman PJ,  Thompson IM,  Meyskens FL Jr,  Goodman GE,  Minasian LM,  Parnes HL,  Klein EA,  Kristal AR
J Natl Cancer Inst 2013 Aug 7;105(15):1132-41
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 23843441
PMC ID: PMC3735464
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

Hershman DL,  Unger JM,  Crew KD,  Minasian LM,  Awad D,  Moinpour CM,  Hansen L,  Lew DL,  Greenlee H,  Fehrenbacher L,  Wade JL 3rd,  Wong SF,  Hortobagyi GN,  Meyskens FL,  Albain KS
J Clin Oncol 2013 Jul 10;31(20):2627-33
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 23733756
PMC ID: PMC3699727

Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.

Azad N,  Yu M,  Davidson B,  Choyke P,  Chen CC,  Wood BJ,  Venkatesan A,  Henning R,  Calvo K,  Minasian L,  Edelman DC,  Meltzer P,  Steinberg SM,  Annunziata CM,  Kohn EC
Mol Cell Proteomics 2013 Jun;12(6):1621-31
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 23449826
PMC ID: PMC3675818

A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment.

Reilly CM,  Bruner DW,  Mitchell SA,  Minasian LM,  Basch E,  Dueck AC,  Cella D,  Reeve BB
Support Care Cancer 2013 Jun;21(6):1525-50
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 23314601
PMC ID: PMC4299699

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

Lee JM,  Hays JL,  Noonan AM,  Squires J,  Minasian L,  Annunziata C,  Wood BJ,  Yu M,  Calvo KR,  Houston N,  Azad N,  Kohn EC
Cancer 2013 Apr 1;119(7):1357-64
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 23280317
PMC ID: PMC3604070

Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.

Jacobs SR,  Weiner BJ,  Minasian LM,  Good MJ
Contemp Clin Trials 2013 Mar;34(2):320-5
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 23295315
PMC ID: PMC3594576

Moving a randomized clinical trial into an observational cohort.

Goodman PJ,  Hartline JA,  Tangen CM,  Crowley JJ,  Minasian LM,  Klein EA,  Cook ED,  Darke AK,  Arnold KB,  Anderson K,  Yee M,  Meyskens FL,  Baker LH
Clin Trials 2013 Feb;10(1):131-42
Major Program(s) or Research Group(s): Office of the Director ;  Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer
PubMed ID: 23064404
PMC ID: PMC3636982
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Challenges and facilitators of community clinical oncology program participation: a qualitative study.

McAlearney AS,  Reiter KL,  Weiner BJ,  Minasian L,  Song PH
J Healthc Manag 2013 Jan-Feb;58(1):29-6
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 23424817
PMC ID: PMC3763953

A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.

Reiter KL,  Song PH,  Minasian L,  Good M,  Weiner BJ,  McAlearney AS
Cancer 2012 Sep 1;118(17):4253-61
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Community Clinical Oncology Program
PubMed ID: 22213241
PMC ID: PMC3323694

Effect of state-mandated insurance coverage on accrual to community cancer clinical trials.

Ellis SD,  Carpenter WR,  Minasian LM,  Weiner BJ
Contemp Clin Trials 2012 Sep;33(5):933-41
Major Program(s) or Research Group(s): Office of the Director ;  Community Oncology and Prevention Trials ;  Community Clinical Oncology Program
PubMed ID: 22683991
PMC ID: PMC3408810

Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

Weiner BJ,  Jacobs SR,  Minasian LM,  Good MJ
J Oncol Pract 2012 Sep;8(5):287-91
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 23277765
PMC ID: PMC3439228

The role of obesity in cancer survival and recurrence.

Demark-Wahnefried W,  Platz EA,  Ligibel JA,  Blair CK,  Courneya KS,  Meyerhardt JA,  Ganz PA,  Rock CL,  Schmitz KH,  Wadden T,  Philip EJ,  Wolfe B,  Gapstur SM,  Ballard-Barbash R,  McTiernan A,  Minasian L,  Nebeling L,  Goodwin PJ
Cancer Epidemiol Biomarkers Prev 2012 Aug;21(8):1244-59
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 22695735
PMC ID: PMC3415558

Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.

Fisch MJ,  Lee JW,  Weiss M,  Wagner LI,  Chang VT,  Cella D,  Manola JB,  Minasian LM,  McCaskill-Stevens W,  Mendoza TR,  Cleeland CS
J Clin Oncol 2012 Jun 1;30(16):1980-8
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 22508819
PMC ID: PMC3383175

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

Marshall JR,  Tangen CM,  Sakr WA,  Wood DP Jr,  Berry DL,  Klein EA,  Lippman SM,  Parnes HL,  Alberts DS,  Jarrard DF,  Lee WR,  Gaziano JM,  Crawford ED,  Ely B,  Ray M,  Davis W,  Minasian LM,  Thompson IM Jr
Cancer Prev Res (Phila) 2011 Nov;4(11):1761-9
Major Program(s) or Research Group(s): Office of the Director ;  Prostate and Urologic Cancer
PubMed ID: 21896650
PMC ID: PMC3208719

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA,  Thompson IM Jr,  Tangen CM,  Crowley JJ,  Lucia MS,  Goodman PJ,  Minasian LM,  Ford LG,  Parnes HL,  Gaziano JM,  Karp DD,  Lieber MM,  Walther PJ,  Klotz L,  Parsons JK,  Chin JL,  Darke AK,  Lippman SM,  Goodman GE,  Meyskens FL Jr,  Baker LH
JAMA 2011 Oct 12;306(14):1549-56
Major Program(s) or Research Group(s): Office of the Director ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer ;  Community Clinical Oncology Program
PubMed ID: 21990298
PMC ID: PMC4169010
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Electronic toxicity monitoring and patient-reported outcomes.

Basch EM,  Reeve BB,  Mitchell SA,  Clauser SB,  Minasian L,  Sit L,  Chilukuri R,  Baumgartner P,  Rogak L,  Blauel E,  Abernethy AP,  Bruner D
Cancer J 2011 Jul-Aug;17(4):231-4
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 21799330
PMC ID: PMC3855320

Conducting cancer control and survivorship research via cooperative groups: a report from the American Society of Preventive Oncology.

Palesh O,  Demark-Wahnefried W,  Mustian K,  Minasian L,  Rowland J,  Sprod L,  Janelsins M,  Peppone L,  Sloan J,  Engquist KB,  Jones L,  Buist D,  Paskett ED
Cancer Epidemiol Biomarkers Prev 2011 May;20(5):1050-5
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 21502540
PMC ID: PMC3124556

Accrual to clinical trials: let's look at the physicians.

Minasian LM,  O'Mara AM
J Natl Cancer Inst 2011 Mar 2;103(5):357-8
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 21317381
PMC ID: not available

Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Bruner DW,  Hanisch LJ,  Reeve BB,  Trotti AM,  Schrag D,  Sit L,  Mendoza TR,  Minasian L,  O'Mara A,  Denicoff AM,  Rowland JH,  Montello M,  Geoghegan C,  Abernethy AP,  Clauser SB,  Castro K,  Mitchell SA,  Burke L,  Trentacosti AM,  Basch EM
Transl Behav Med 2011 Mar;1(1):110-22
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 24073038
PMC ID: PMC3717706

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Price DK,  Chau CH,  Till C,  Goodman PJ,  Baum CE,  Ockers SB,  English BC,  Minasian L,  Parnes HL,  Hsing AW,  Reichardt JK,  Hoque A,  Tangen CM,  Kristal AR,  Thompson IM,  Figg WD
J Urol 2010 Dec;184(6):2297-302
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 20952028
PMC ID: PMC3930175
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Freedman AN,  Sansbury LB,  Figg WD,  Potosky AL,  Weiss Smith SR,  Khoury MJ,  Nelson SA,  Weinshilboum RM,  Ratain MJ,  McLeod HL,  Epstein RS,  Ginsburg GS,  Schilsky RL,  Liu G,  Flockhart DA,  Ulrich CM,  Davis RL,  Lesko LJ,  Zineh I,  Randhawa G,  Ambrosone CB,  Relling MV,  Rothman N,  Xie H,  Spitz MR,  Ballard-Barbash R,  Doroshow JH,  Minasian LM
J Natl Cancer Inst 2010 Nov 17;102(22):1698-705
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 20944079
PMC ID: PMC2982809

Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program.

Minasian LM,  Carpenter WR,  Weiner BJ,  Anderson DE,  McCaskill-Stevens W,  Nelson S,  Whitman C,  Kelaghan J,  O'Mara AM,  Kaluzny AD
Cancer 2010 Oct 1;116(19):4440-9
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 20572032
PMC ID: PMC2945622

Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.

Trimble EL,  Birrer MJ,  Hoskins WJ,  Marth C,  Petryshyn R,  Quinn M,  Thomas GM,  Kitchener HC,  Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee,  Aghajanian C,  Alberts DS,  Armstrong D,  Brown J,  Coleman RL,  Colombo N,  Eisenhauer E,  Friedlander M,  Fujiwara K,  Hunsberger S,  Kaye S,  Ledermann JA,  Lee S,  Look K,  Mannel R,  McNeish IA,  Minasian L,  Oza A,  Paul J,  Poveda A,  Pujade-Lauraine E,  Schoenfeldt M,  Swart AM,  von Gruenigen V,  Wenzel L
Int J Gynecol Cancer 2010 Oct;20(7):1290-8
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 21151709
PMC ID: PMC2998994

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Sarosy GA,  Hussain MM,  Seiden MV,  Fuller AF,  Nikrui N,  Goodman A,  Minasian L,  Reed E,  Steinberg SM,  Kohn EC
Cancer 2010 Mar 15;116(6):1476-84
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 20091841
PMC ID: PMC2836408

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.

Lee JM,  Sarosy GA,  Annunziata CM,  Azad N,  Minasian L,  Kotz H,  Squires J,  Houston N,  Kohn EC
Br J Cancer 2010 Feb 2;102(3):495-9
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 20051952
PMC ID: PMC2822947

Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial.

Cook ED,  Arnold KB,  Hermos JA,  McCaskill-Stevens W,  Moody-Thomas S,  Probstfield JL,  Hamilton SJ,  Campbell RD,  Anderson KB,  Minasian LM
Clin Trials 2010 Feb;7(1):90-9
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Community Clinical Oncology Program ;  Prostate and Urologic Cancer
PubMed ID: 20156960
PMC ID: PMC3956599
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

Annunziata CM,  Walker AJ,  Minasian L,  Yu M,  Kotz H,  Wood BJ,  Calvo K,  Choyke P,  Kimm D,  Steinberg SM,  Kohn EC
Clin Cancer Res 2010 Jan 15;16(2):664-72
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 20068097
PMC ID: PMC2943831

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Dunn BK,  Richmond ES,  Minasian LM,  Ryan AM,  Ford LG
Nutr Cancer 2010;62(7):896-918
Major Program(s) or Research Group(s): Gastrointestinal and Other CancersChemopreventive Agent Development ;  Community Clinical Oncology Program ;  Prostate and Urologic CancerCommunity Oncology and Prevention Trials
PubMed ID: 20924966
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.

Azad N,  Perroy A,  Gardner E,  Imamura CK,  Graves C,  Sarosy GA,  Minasian L,  Kotz H,  Raggio M,  Figg WD,  Kohn EC
Cancer Biol Ther 2009 Oct;8(19):1800-5
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 19738417
PMC ID: PMC3104675

Learning from experience.

Trimble EL,  McCaskill-Stevens W,  Denicoff A,  Minig L,  Minasian LM
Oncologist 2009 May;14(5):476-7
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 19417099
PMC ID: not available

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM,  Klein EA,  Goodman PJ,  Lucia MS,  Thompson IM,  Ford LG,  Parnes HL,  Minasian LM,  Gaziano JM,  Hartline JA,  Parsons JK,  Bearden JD 3rd,  Crawford ED,  Goodman GE,  Claudio J,  Winquist E,  Cook ED,  Karp DD,  Walther P,  Lieber MM,  Kristal AR,  Darke AK,  Arnold KB,  Ganz PA,  Santella RM,  Albanes D,  Taylor PR,  Probstfield JL,  Jagpal TJ,  Crowley JJ,  Meyskens FL Jr,  Baker LH,  Coltman CA Jr
JAMA 2009 Jan 7;301(1):39-51
Major Program(s) or Research Group(s): Prostate and Urologic Cancer ;  Community Clinical Oncology Program ;  Community Oncology and Prevention Trials
PubMed ID: 19066370
PMC ID: PMC3682779
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.

Demark-Wahnefried W,  Polascik TJ,  George SL,  Switzer BR,  Madden JF,  Ruffin MT 4th,  Snyder DC,  Owzar K,  Hars V,  Albala DM,  Walther PJ,  Robertson CN,  Moul JW,  Dunn BK,  Brenner D,  Minasian L,  Stella P,  Vollmer RT
Cancer Epidemiol Biomarkers Prev 2008 Dec;17(12):3577-87
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 19064574
PMC ID: PMC2703189

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Azad NS,  Posadas EM,  Kwitkowski VE,  Steinberg SM,  Jain L,  Annunziata CM,  Minasian L,  Sarosy G,  Kotz HL,  Premkumar A,  Cao L,  McNally D,  Chow C,  Chen HX,  Wright JJ,  Figg WD,  Kohn EC
J Clin Oncol 2008 Aug 1;26(22):3709-14
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18669456
PMC ID: not available

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Azad NS,  Annunziata CM,  Steinberg SM,  Minasian L,  Premkumar A,  Chow C,  Kotz HL,  Kohn EC
Cancer 2008 Apr 15;112(8):1726-32
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18300236
PMC ID: not available

Intraperitoneal chemotherapy for women with epithelial ovarian cancer.

Trimble EL,  Thompson S,  Christian MC,  Minasian L
Oncologist 2008 Apr;13(4):403-9
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 18448554
PMC ID: not available

A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Greene MH,  Piedmonte M,  Alberts D,  Gail M,  Hensley M,  Miner Z,  Mai PL,  Loud J,  Rodriguez G,  Basil J,  Boggess J,  Schwartz PE,  Kelley JL,  Wakeley KE,  Minasian L,  Skates S
Cancer Epidemiol Biomarkers Prev 2008 Mar;17(3):594-604
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Community Clinical Oncology Program
PubMed ID: 18349277
PMC ID: PMC3125978

Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.

Lipscomb J,  Reeve BB,  Clauser SB,  Abrams JS,  Bruner DW,  Burke LB,  Denicoff AM,  Ganz PA,  Gondek K,  Minasian LM,  O'Mara AM,  Revicki DA,  Rock EP,  Rowland JH,  Sgambati M,  Trimble EL
J Clin Oncol 2007 Nov 10;25(32):5133-40
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 17991933
PMC ID: not available

Health-related quality of life and symptom management research sponsored by the National Cancer Institute.

Minasian LM,  O'Mara AM,  Reeve BB,  Denicoff AM,  Kelaghan J,  Rowland JH,  Trimble EL,  National Cancer Institute
J Clin Oncol 2007 Nov 10;25(32):5128-32
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsSupportive Care and Symptom Management
PubMed ID: 17991932
PMC ID: not available

Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.

Buchanan DR,  O'Mara AM,  Kelaghan JW,  Sgambati M,  McCaskill-Stevens W,  Minasian L
Cancer 2007 Oct 1;110(7):1621-8
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 17868120
PMC ID: not available

A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.

Posadas EM,  Kwitkowski V,  Kotz HL,  Espina V,  Minasian L,  Tchabo N,  Premkumar A,  Hussain MM,  Chang R,  Steinberg SM,  Kohn EC
Cancer 2007 Jul 15;110(2):309-17
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 17559139
PMC ID: not available

Determinants of implementation effectiveness: adapting a framework for complex innovations.

Helfrich CD,  Weiner BJ,  McKinney MM,  Minasian L
Med Care Res Rev 2007 Jun;64(3):279-303
Major Program(s) or Research Group(s): Office of the Director ;  Community Oncology and Prevention Trials ;  Community Clinical Oncology Program
PubMed ID: 17507459
PMC ID: not available

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Posadas EM,  Liel MS,  Kwitkowski V,  Minasian L,  Godwin AK,  Hussain MM,  Espina V,  Wood BJ,  Steinberg SM,  Kohn EC
Cancer 2007 Apr 1;109(7):1323-30
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 17330838
PMC ID: PMC2778218

Symptom control trials: a 20-year experience.

Loprinzi CL,  Barton DL,  Jatoi A,  Sloan J,  Martenson J,  Steensma D,  Rao R,  Novotny P,  Sood A,  Grothey A,  Minasian L,  Windschitl H
J Support Oncol 2007 Mar;5(3):119-25, 128
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 17410810
PMC ID: not available

Proteomics in clinical trials and practice: present uses and future promise.

Azad NS,  Rasool N,  Annunziata CM,  Minasian L,  Whiteley G,  Kohn EC
Mol Cell Proteomics 2006 Oct;5(10):1819-29
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 16737951
PMC ID: not available

Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.

Marshall JR,  Sakr W,  Wood D,  Berry D,  Tangen C,  Parker F,  Thompson I,  Lippman SM,  Lieberman R,  Alberts D,  Jarrard D,  Coltman C,  Greenwald P,  Minasian L,  Crawford ED
Cancer Epidemiol Biomarkers Prev 2006 Aug;15(8):1479-84
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 16896036
PMC ID: not available

Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.

Sabichi AL,  Lee JJ,  Taylor RJ,  Thompson IM,  Miles BJ,  Tangen CM,  Minasian LM,  Pisters LL,  Caton JR,  Basler JW,  Lerner SP,  Menter DG,  Marshall JR,  Crawford ED,  Lippman SM
Clin Cancer Res 2006 Apr 1;12(7 Pt 1):2178-84
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 16609032
PMC ID: not available

Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.

Buchanan DR,  White JD,  O'Mara AM,  Kelaghan JW,  Smith WB,  Minasian LM
J Clin Oncol 2005 Sep 20;23(27):6682-9
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 16170176
PMC ID: not available

Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience.

McCaskill-Stevens W,  McKinney MM,  Whitman CG,  Minasian LM
J Clin Oncol 2005 Aug 1;23(22):5247-54
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Community Clinical Oncology Program
PubMed ID: 16051967
PMC ID: not available

Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program.

Buchanan DR,  O'Mara AM,  Kelaghan JW,  Minasian LM
J Clin Oncol 2005 Jan 20;23(3):591-8
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials
PubMed ID: 15659506
PMC ID: not available

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM,  Goodman PJ,  Klein EA,  Parnes HL,  Thompson IM Jr,  Kristal AR,  Santella RM,  Probstfield JL,  Moinpour CM,  Albanes D,  Taylor PR,  Minasian LM,  Hoque A,  Thomas SM,  Crowley JJ,  Gaziano JM,  Stanford JL,  Cook ED,  Fleshner NE,  Lieber MM,  Walther PJ,  Khuri FR,  Karp DD,  Schwartz GG,  Ford LG,  Coltman CA Jr
J Natl Cancer Inst 2005 Jan 19;97(2):94-102
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director ;  Prostate and Urologic Cancer ;  Community Clinical Oncology Program
PubMed ID: 15657339
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Cook ED,  Moody-Thomas S,  Anderson KB,  Campbell R,  Hamilton SJ,  Harrington JM,  Lippman SM,  Minasian LM,  Paskett ED,  Craine S,  Arnold KB,  Probstfield JL
Clin Trials 2005;2(5):436-42
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Community Clinical Oncology Program ;  Prostate and Urologic Cancer
PubMed ID: 16315648
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM,  Pauler DK,  Goodman PJ,  Tangen CM,  Lucia MS,  Parnes HL,  Minasian LM,  Ford LG,  Lippman SM,  Crawford ED,  Crowley JJ,  Coltman CA Jr
N Engl J Med 2004 May 27;350(22):2239-46
Major Program(s) or Research Group(s): Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer ;  Office of the Director
PubMed ID: 15163773
PMC ID: not available
Clinical Trials: Prostate Cancer Prevention Trial (PCPT)

Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.

Hussain MM,  Kotz H,  Minasian L,  Premkumar A,  Sarosy G,  Reed E,  Zhai S,  Steinberg SM,  Raggio M,  Oliver VK,  Figg WD,  Kohn EC
J Clin Oncol 2003 Dec 1;21(23):4356-63
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 14645425
PMC ID: not available

Prevention and early detection clinical trials: opportunities for primary care providers and their patients.

Ford LG,  Minasian LM,  McCaskill-Stevens W,  Pisano ED,  Sullivan D,  Smith RA
CA Cancer J Clin 2003 Mar-Apr;53(2):82-101
Major Program(s) or Research Group(s): Community Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 12691266
PMC ID: not available

A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.

Kohn EC,  Reed E,  Sarosy GA,  Minasian L,  Bauer KS,  Bostick-Bruton F,  Kulpa V,  Fuse E,  Tompkins A,  Noone M,  Goldspiel B,  Pluda J,  Figg WD,  Liotta LA
Clin Cancer Res 2001 Jun;7(6):1600-9
Major Program(s) or Research Group(s): Office of the Director
PubMed ID: 11410496
PMC ID: not available